In the pathogenesis of psoriasis, IL-23-mediated activation of the Th17 pathway is regarded as the central inflammatory cascade [87], and biologics, such as TNF-α inhibitors, IL-23 inhibitors, and IL-17 inhibitors, have been used for the treatment of psoriasis [85]. This evidence concerns the gene TNF and psoriasis.